These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24825486)

  • 1. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.
    Ling W; Chang L; Hillhouse M; Ang A; Striebel J; Jenkins J; Hernandez J; Olaer M; Mooney L; Reed S; Fukaya E; Kogachi S; Alicata D; Holmes N; Esagoff A
    Addiction; 2014 Sep; 109(9):1489-500. PubMed ID: 24825486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial.
    Rezaei F; Emami M; Zahed S; Morabbi MJ; Farahzadi M; Akhondzadeh S
    Daru; 2015 Jan; 23(1):2. PubMed ID: 25588930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
    Miles SW; Sheridan J; Russell B; Kydd R; Wheeler A; Walters C; Gamble G; Hardley P; Jensen M; Kuoppasalmi K; Tuomola P; Föhr J; Kuikanmäki O; Vorma H; Salokangas R; Mikkonen A; Kallio M; Kauhanen J; Kiviniemi V; Tiihonen J
    Addiction; 2013 Jul; 108(7):1279-86. PubMed ID: 23297867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.
    Konstenius M; Jayaram-Lindström N; Guterstam J; Beck O; Philips B; Franck J
    Addiction; 2014 Mar; 109(3):440-9. PubMed ID: 24118269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder.
    Aryan N; Banafshe HR; Farnia V; Shakeri J; Alikhani M; Rahimi H; Sehat M; Mamsharifi P; Ghaderi A; Omidi A
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):72. PubMed ID: 32977820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
    Huss M; Ginsberg Y; Tvedten T; Arngrim T; Philipsen A; Carter K; Chen CW; Kumar V
    Adv Ther; 2014 Jan; 31(1):44-65. PubMed ID: 24371021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
    Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
    J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence.
    Heinzerling KG; Swanson AN; Kim S; Cederblom L; Moe A; Ling W; Shoptaw S
    Drug Alcohol Depend; 2010 Jun; 109(1-3):20-9. PubMed ID: 20092966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
    Konstenius M; Jayaram-Lindström N; Beck O; Franck J
    Drug Alcohol Depend; 2010 Apr; 108(1-2):130-3. PubMed ID: 20015599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis.
    Chan B; Freeman M; Kondo K; Ayers C; Montgomery J; Paynter R; Kansagara D
    Addiction; 2019 Dec; 114(12):2122-2136. PubMed ID: 31328345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.
    Huss M; Ginsberg Y; Arngrim T; Philipsen A; Carter K; Chen CW; Gandhi P; Kumar V
    Clin Drug Investig; 2014 Sep; 34(9):639-49. PubMed ID: 25015027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.
    Winhusen TM; Somoza EC; Brigham GS; Liu DS; Green CA; Covey LS; Croghan IT; Adler LA; Weiss RD; Leimberger JD; Lewis DF; Dorer EM
    J Clin Psychiatry; 2010 Dec; 71(12):1680-8. PubMed ID: 20492837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.
    Heinzerling KG; Briones M; Thames AD; Hinkin CH; Zhu T; Wu YN; Shoptaw SJ
    J Neuroimmune Pharmacol; 2020 Jun; 15(2):238-248. PubMed ID: 31820289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.
    Levin FR; Evans SM; Brooks DJ; Garawi F
    Drug Alcohol Depend; 2007 Feb; 87(1):20-9. PubMed ID: 16930863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ling et al.'s 'Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder'.
    Levin FR; Mariani JJ; Bisaga A; Nunes EV
    Addiction; 2015 May; 110(5):875-6. PubMed ID: 25808040
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.